高容量HDF的获益证据与实现  

Evidence of benefits and achievement of high-volume hemodiafiltration

作　　者：杜卉 左力[2] DU Hui;ZUO Li(Global Medical Office,Fresenius Medical Care,Beijing 100028,China;Department of Nephrology,Peking University People’s Hospital,Beijing 100044,China)

机构地区：[1]费森尤斯医疗全球医疗办公室,北京100028 [2]北京大学人民医院肾内科,北京100044

出　　处：《中国血液净化》2024年第4期241-244,289,共5页Chinese Journal of Blood Purification

摘　　要：血液透析滤过(hemodiafiltration,HDF)结合了弥散与对流的溶质清除方式,以更好地清除较大分子量的尿毒症毒素。该治疗模式是否可以为需要肾脏替代治疗的终末期肾病(end-stage renal disease,ESRD)患者带来长期生存获益一直存有争议,近期高剂量HDF与高通量血液透析的比较(comparison of high-dose hemodiafiltration with high-flux hemodialysis,CONVINCE)研究结果的发表或将成为该争议终结的里程碑。本综述系统梳理了HDF临床获益的证据以及高容量HDF实现的重要影响因素和阶梯式实现方案。Hemodiafiltration(HDF)works by combining diffusive and convective solute removal to provide a greater removal of larger molecular weight uremic toxins.The recent publication of the CONVINCE study might be a milestone in ending the controversy over whether this treatment modality can provide longterm survival benefits for patients with end-stage renal disease(ESRD)requiring renal replacement therapy.This review gives a brief overview of the current evidence for the clinical benefits of HDF as well as the important factors and stepwise protocols for high-volume HDF achievements.

关 键 词：血液透析滤过 肾脏替代治疗 终末期肾病 

分 类 号：R459.5[医药卫生—治疗学]